2022 – an excellent year for the Hb portfolio
This year has been especially successful for the Hb 801 system, which was introduced to several new countries. The revenue growth has passed more than 50% from 2021.
Part of this growth comes from Thailand, where we successfully placed 200 analyzers in hospitals. This was made possible because of the hospital claim on the system combined with the excellent work from local sales.
US has, since the launch in 2019, placed more than 11,000 Hb 801 analyzers on the market, which is quite an achievement. This has surely had an impact on the limited success of the introduction of the competing private label system from McKesson.
We have also seen great achievement in France with a successful introduction of the Hb 801 to the firemen that are running the ambulance services.
Many of these stories can be partly credited to the relentless work from the HemoCue Headquarters. We have worked to expand the Intended Use of the system, and the MarCom/Product Management Team has run some excellent campaigns on Anemia in combination with WBC DIFF within Elderly Care, and the benefits of having the Hb 801 in road ambulances.
Another great story worth highlighting is from the complaint department. Out of all the HemoCue systems, the Hb 801 is the system that has the lowest complaint rate. A truly great system in all aspects.
There are many more success stories on the way in combination with the Hb 801 Exchange campaign that will kick off in Q1 2023. So, stay tuned for more great news on the Hb 801 system soon…